Elicio Therapeutics, Inc.
NASDAQ Global MarketRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Elicio Therapeutics, Inc. (Nasdaq: ELTX) is a clinical-stage biotechnology company that develops lymph node-targeted immunotherapies based on its proprietary Amphiphile (AMP) platform to treat cancers, including mutant KRAS-driven solid tumors such as pancreatic ductal adenocarcinoma and colorectal cancer. The company offers ELI-002, a multivalent AMP peptide vaccine in Phase 2 trials (AMPLIFY-7P) targeting seven common KRAS mutations; ELI-007, a preclinical AMP vaccine for BRAF-driven cancers; ELI-008, a preclinical AMP vaccine for p53-mutated cancers; and earlier-stage candidates including ELI-004 (adjuvant), ELI-011 (hematological cancers), and ELI-012 (mKRAS TCR T cell amplifier). Founded in 2011 and headquartered in Boston, Massachusetts, Elicio conducts operations primarily in the United States with clinical trials at international sites. Recent developments include a $10 million senior secured financing from GKCC, LLC in June 2025 to fund operations into Q1 2026 and support the AMPLIFY-7P Phase 2 interim analysis; alignment with the FDA on ELI-002 Phase 3 registrational strategy; publication of updated Phase 1 AMPLIFY-201 data in Nature Medicine showing 16.3-month median recurrence-free survival; an investigator-initiated Phase 1 neoadjuvant trial for ELI-002 by Memorial Sloan Kettering Cancer Center funded by the Lustgarten Foundation; and the appointment of Marc J. Wolfgang as Chief Technology Officer in November 2025.
Company News
Elicio Therapeutics to Participate at the H.C. Wainwright 28th Annual Global Investment Conference
Elicio Therapeutics to Participate at the Wells Fargo 21st Annual Healthcare Conference
Elicio Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Updates
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Elicio Therapeutics, Inc. - ELTX
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Elicio Therapeutics, Inc. - ELTX
Elicio Therapeutics Announces Closing of $15 Million Registered Direct Offering
Elicio Therapeutics Announces Pricing of $15 Million Registered Direct Offering
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Elicio Therapeutics, Inc. - ELTX
Elicio Therapeutics Added to Russell 2000® and Russell 3000® Indexes
ELTX Investors Have Opportunity to Join Elicio Therapeutics, Inc. Fraud Investigation with the Schall Law Firm
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Elicio Therapeutics, Inc. - ELTX
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Elicio Therapeutics, Inc. - ELTX
Elicio Therapeutics Points To Durable Responses As It Maps Next Steps For Lead Cancer Drug
Elicio Therapeutics Reports Multiple Complete Responses After ELI-002 7P Treatment and Subsequent Therapy with Checkpoint Inhibition in Metastatic mKRAS Pancreatic Cancer
Elicio Therapeutics Investigation Initiated: SueWallSt Investigates the Officers and Directors of Elicio Therapeutics (ELTX)
Elicio Therapeutics Pancreatic Cancer Study Disappoints
ELTX INVESTOR ALERT: Holzer & Holzer, LLC Investigation of Elicio Therapeutics, Inc.
Elicio shares tumble after pancreatic cancer therapy misses mid-stage study goal
Elicio Therapeutics Reports Results from Phase 2 AMPLIFY-7P Study and Outlines Refined Phase 3 Development Strategy for ELI-002 7P in Adjuvant Pancreatic Cancer
Elicio Therapeutics Reports Results from Phase 2 AMPLIFY-7P Study and Outlines Refined Phase 3 Development Strategy for ELI-002 7P in Adjuvant Pancreatic Cancer